BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25137021)

  • 21. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
    Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
    BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
    Fu Q; Liu Z; Pan D; Zhang W; Xu L; Zhu Y; Liu H; Xu J
    Cancer Sci; 2014 Nov; 105(11):1427-34. PubMed ID: 25155155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney.
    Presti JC; Wilhelm M; Reuter V; Russo P; Motzer R; Waldman F
    J Urol; 2002 Mar; 167(3):1464-8. PubMed ID: 11832771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
    Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
    BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of chromosome 9p status in renal cell carcinoma: a systematic review and quality of the reported studies.
    El-Mokadem I; Fitzpatrick J; Rai B; Cunningham J; Pratt N; Fleming S; Nabi G
    Biomed Res Int; 2014; 2014():521380. PubMed ID: 24877109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.
    Yoshikawa Y; Yamada Y; Emi M; Atanesyan L; Smout J; de Groot K; Savola S; Nakanishi-Shinkai Y; Kanematsu A; Nojima M; Ohmuraya M; Hashimoto-Tamaoki T; Yamamoto S
    Cancer Sci; 2022 Jan; 113(1):297-307. PubMed ID: 34687579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma.
    Bai Q; Liu L; Xia Y; Wang J; Xi W; Qu Y; Xiong Y; Long Q; Xu J; Guo J
    Oncotarget; 2017 Jul; 8(27):44186-44194. PubMed ID: 28562332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of 9p21 Regulatory Hub Promotes Kidney Cancer Progression by Upregulating HOXB13.
    Baietti MF; Zhao P; Crowther J; Sewduth RN; De Troyer L; Debiec-Rychter M; Sablina AA
    Mol Cancer Res; 2021 Jun; 19(6):979-990. PubMed ID: 33619226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
    Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
    BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis.
    Zhang Y; Zhu X; Qiao X; Sun L; Tian Y; Yang Y; Zhao Y; Liu C
    Int J Med Sci; 2020; 17(17):2819-2825. PubMed ID: 33162809
    [No Abstract]   [Full Text] [Related]  

  • 34. Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma.
    Mehra R; Nallandhighal S; Cotta B; Knuth Z; Su F; Kasputis A; Zhang Y; Wang R; Cao X; Udager AM; Dhanasekaran SM; Cieslik MP; Morgan TM; Salami SS
    JCO Precis Oncol; 2024 May; 8():e2300565. PubMed ID: 38810179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
    Liu Y; Liu H; Liu W; Zhang W; An H; Xu J
    World J Urol; 2015 Nov; 33(11):1791-9. PubMed ID: 25630622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
    Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
    BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC).
    Fukushima H; Saito K; Yasuda Y; Tanaka H; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
    Clin Genitourin Cancer; 2020 Apr; 18(2):111-116.e1. PubMed ID: 32001181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
    Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
    Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
    Parker WP; Cheville JC; Frank I; Zaid HB; Lohse CM; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2017 Apr; 71(4):665-673. PubMed ID: 27287995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.